Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 93

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 93
---
 on travel imposed or recommended by federal or state governments, employers and others
or interruption of clinical trial participant visits and study procedures that are deemed nonessential, which may impact the integrity
of participant data and clinical trial endpoints; and

●interruption or delays in the operations of the FDA, European
Medicines Agency or other regulatory authorities, which may impact review and approval timelines.

48

The extent to which an outbreak impacts our business will depend on
future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of any
disease, the duration of any pandemic, travel restrictions and social distancing in the United States and other countries, business
closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat
the disease.

Shareholder litigation and regulatory inquiries and investigations
are expensive and could harm the Company’s business, financial condition and operating results and could divert management attention.

Since securities class action litigation and/or stockholder derivative
litigation and inquiries or investigations by regulatory authorities often follows significant business transactions, such as the sale
of a company or announcement of any other strategic transaction, such as the Business Combination, we may become subject to those types
of lawsuits or investigations. Shareholder activism, which could take many forms or arise in a variety of situations, has been increasing
recently. Any stockholder litigation, stockholder activism, including potential proxy contests, and/or regulatory investigations against
the Company, whether or not resolved in the Company’s favor, could result in substantial costs and divert the Company’s management’s
attention from other business concerns, which could adversely affect the Company’s business and cash resources and the ultimate
value the Company’s shareholders receive as a result of the Business Combination.

We may be the target of securities class action and derivative
lawsuits which could result in substantial costs.

Our share price may be volatile and, in the past, companies that have
experienced volatility in the market price of their stock have been subject to securities litigation, including class action litigation.
We may be the target of this type of litigation in the future. Even if the lawsuits are without merit, defending against these claims
can result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which
could have a negative impact on our liquidity and financial condition. We cannot predict whether any such lawsuits will be filed.

The outcome of any future claims and litigation could have a
material adverse